- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05752461
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
April 20, 2023 updated by: Beijing Suncadia Pharmaceuticals Co., Ltd
A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee Arthroplasty
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
316
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhuang Nie
- Phone Number: +0518-82342973
- Email: zhuang.nie@hengrui.com
Study Contact Backup
- Name: Xiaojian Gao
- Phone Number: +8618510128450,
- Email: xiaojian.gao@hengrui.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital Central South University
-
Principal Investigator:
- Guanghua Lei
-
Principal Investigator:
- Wenfeng Xiao
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Understand the research procedures and methods, volunteer to participate in the study, and sign the informed consent
- Scheduled to undergo elective unilateral total knee arthroplayts (TKA)
- Male or female(≥ 40 years old and < 80 years old)
Exclusion Criteria:
- Unable to receive CT angiography of both lower limbs;
- Malignant tumor within one year of the screening ;
- History of venous thromboembolism;
- Myocardial infarction, transient ischemic attack or ischemic stroke occurred within 6 months of the screening;
- Any medical history that may increase the risk of bleeding or any conditions that the investigator considers to increase the risk of bleeding
Any of the laboratory test indicators meets the following criteria:
①estimated Glomerular Filtration Rate < 60 mL/min/1.73m2 ;
②Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal value (ULN);
③total bilirubin was > 2 times, etc
- History of drug abuse;
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group A: SHR-2004 injection
|
low dose subcutaneous injection once
medium dose subcutaneous injection once
high dose subcutaneous injection once
|
Experimental: Treatment group B: SHR-2004 injection
|
low dose subcutaneous injection once
medium dose subcutaneous injection once
high dose subcutaneous injection once
|
Experimental: Treatment group C: SHR-2004 injection
|
low dose subcutaneous injection once
medium dose subcutaneous injection once
high dose subcutaneous injection once
|
Active Comparator: Treatment group D: Enoxaparin sodium injection
|
40 mg administered as subcutaneous injection once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral CT venography, confirmed symptomatic DVT, non-fatal PE and all-cause death(Primary efficacy outcome)
Time Frame: Day 12
|
Day 12
|
Incidence of composite endpoint of major and clinically relevant non-major bleeding(Primary safety outcome)
Time Frame: Day 12
|
Day 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral CT venography, confirmed symptomatic DVT, non-fatal PE and all-cause death(Secondary efficacy endpoint)
Time Frame: Day 85
|
Day 85
|
Incidence of composite endpoint of any bleeding(Secondary safety endpoint)
Time Frame: Day 12
|
Day 12
|
Incidence of composite endpoint of major and clinically relevant non-major bleeding(Secondary safety endpoint)
Time Frame: Day 85
|
Day 85
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2023
Primary Completion (Anticipated)
June 15, 2024
Study Completion (Anticipated)
September 30, 2024
Study Registration Dates
First Submitted
February 22, 2023
First Submitted That Met QC Criteria
February 22, 2023
First Posted (Actual)
March 2, 2023
Study Record Updates
Last Update Posted (Actual)
April 24, 2023
Last Update Submitted That Met QC Criteria
April 20, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-2004-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Venous Thromboembolism After Knee Arthroplasty
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Boehringer IngelheimCompletedVenous Thrombosis | Arthroplasty, Replacement, KneeJapan
-
Suzhou Alphamab Co., Ltd.RecruitingKnee Arthroplasty, TotalChina
-
Boehringer IngelheimCompletedThromboembolism | Arthroplasty, Replacement, KneeUnited States, Canada, Mexico, United Kingdom
-
BayerCompletedKnee Arthroplasty, TotalLithuania, Spain, Bulgaria, Israel, Poland, Czechia, Greece, Russian Federation, Latvia, Portugal, Ukraine, Canada, South Africa
-
Boehringer IngelheimCompletedArthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)Austria, Canada, Czechia, Finland, Netherlands, Sweden
-
Daiichi Sankyo Co., Ltd.CompletedDeep Vein Thrombosis | Venous Thromboembolism | Total Knee ArthroplastyJapan
Clinical Trials on SHR-2004 injection
-
Beijing Suncadia Pharmaceuticals Co., LtdNot yet recruiting
-
Beijing Suncadia Pharmaceuticals Co., LtdActive, not recruitingPrevention of Arterial and Venous ThrombosisChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Guangdong Hengrui Pharmaceutical Co., LtdRecruitingChronic Rhinosinusitis With Nasal PolypsChina
-
Guangdong Hengrui Pharmaceutical Co., LtdCompleted
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
Henan Cancer HospitalRecruitingHER2 Low Breast CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingNasopharyngeal CarcinomaChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Enrolling by invitationModerate to Severe Atopic DermatitisChina